← All trials
NCT04203342
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 6, 2020
- Primary completion
- May 28, 2020
- Completion date
- Jul 13, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 675
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Douglas PharmaceuticalsLead sponsor
- Novum Pharmaceutical Research ServicesCollaborator
- ACM Global LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.